Kornimate/medical-research-clean huggingface dataset:
physical activity and inactivity in lung cancer survivors

Conditions: Lung Cancer Survivors

Summary: the purpose of this study is to learn how often lung cancer survivors exercise. we also want to learn what helps people to be active or prevents them from being active. learning this will help us to expand services for lung cancer survivors.

despite the potential benefits of physical activity, particularly for cancer survivors with comorbid pulmonary and cardiac conditions, no previous research has examined the physical activity levels of lung cancer survivors, an underrepresented subpopulation in cancer survivorship research. we address this research gap in the current study, in which a random sample of 200 lung cancer survivors will complete a comprehensive telephone interview or use self-report to complete a questionnaire focusing on physical activity, related covariates, and preferences regarding physical activity counseling and interventions. we estimate the total time for the completion of the interview or self-report questionnaire to be 45-60 minutes. this study will be conducted with survivors of primary lung cancer who are from 1 to 5 years posttreatment and were treated at memorial sloan-kettering cancer center (mskcc).

Eligibility criteria:
inclusion criteria: * diagnosis of primary stage ia or ib nsclc; * underwent surgical resection for nsclc at mskcc; * from 1 to 5 years post-treatment for nsclc prior to study recruitment; * no evidence of disease (ned) at the time of recruitment; * can be reached by telephone; * able to provide informed consent. exclusion criteria: * undergoing active antineoplastic treatment; * major psychopathology or cognitive impairment likely in the judgment of the investigator to interfere with participation and compliance with the protocol.

Keywords: lung cancer survivor lung
establishment of clinical prediction model for postoperative symptomatic spinal epidural hematoma

Conditions: Spinal Epidural Hematoma

Summary: the goal of this observational study is to establish a clinical prediction model based on artificial intelligence algorithms for patients with postoperative symptomatic spinal epidural hematoma(psseh) after spinal surgery. the investigators will collect the features of 2000 patients as the training set to train the models using ai algorithms, then recruit a prospective cohort of 2000 patients to test if the trained model is precise and consistent to predict the occurrence of psseh as well as to find out whether there is any new risk factor of psseh.

firstly, the investigators plan to collect the features of 2000 patients who received spinal surgery at peking university third hospital from january 2014 to december 2024, including those with psseh and the controls, as the training set to build up a prediction model based on multiple ai algorithms. then, the investigators will choose the optimal model through comparing various features, assessing the robustness of the model quantitatively using k-fold cross validation and exploring the influence of all features on the output of the final model by means such as shap. lastly, the investigators will recruit a prospective cohort of approximately 2000 patients who receive spinal surgery from january 2025 to december 2026 at peking university third hospital and collect the same features as the training set to test if the trained prediction model is precise and consistent to predict the occurrence of psseh and whether there is any feature , undiscovered before, that is strongly related to psseh.

Eligibility criteria:
inclusion criteria: * patients who will receive spinal surgery from january 2025 to december 2026 at peking university third hospital exclusion criteria: * patients with a history of lumbar trauma before admission; * patients who suffer from malignant tumor; * patients with systemic infection; * patients who quit the study midway

Keywords: artificial intelligence algorithm clinical prediction model postoperative symptomatic spinal epidural hematoma
a study of mircera in anemic patients with chronic kidney disease not yet on dialysis.

Conditions: Anemia

Summary: this study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of mircera in anemic patients with chronic kidney disease not yet on dialysis. the anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * chronic renal anemia; * not receiving renal replacement therapy. exclusion criteria: * women who are pregnant, breastfeeding or using unreliable birth control methods; * administration of any investigational drug within 30 days preceding the screening visit and during the run-in period.
a study comparing the efficacy and safety of duloxetine and placebo for the treatment of depression in elderly patients

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age). patients who do not respond in the first 13 weeks will be eligible for rescue using pre-defined criteria. patients randomized to duloxetine 60 mg/day meeting the rescue criteria will be increased to 120 mg/day. patients randomized to the placebo arm meeting the rescue criteria will be assigned to duloxetine 60 mg/day.


Eligibility criteria:
inclusion criteria: * are male or female outpatients at least 65 years of age who meet the diagnostic and statistical manual of mental disorders fourth edition text revision (dsm-iv-tr) diagnostic criteria for major depressive disorder (mdd) * have a mini mental score exam (mmse) score of at least 20 at visit 1 * have a degree of understanding such that the patient can communicate intelligibly with the investigator and study coordinator exclusion criteria: * patients judged clinically to be at serious suicidal risk in the opinion of the investigator * have any prior history of bipolar disorder, panic disorder, psychosis, schizophrenia, or obsessive-compulsive disorder * have any current (within the past 12 months) dsm-iv-tr primary axis i diagnosis other than mdd * have moderate to severe dementia * have a serious medical illness, including any cardiovascular (cv), hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require hospitalization within 6 months, in the opinion of the investigator
study of bortezomib and dexamethasone with or without elotuzumab to treat relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of the study is to determine whether the addition of elotuzumab to bortezomib/ dexamethasone will prolong the time before myeloma worsens \[progression free survival (pfs)\].


Eligibility criteria:
for additional information, please contact the bms oncology clinical trial information service at 855-216-0126 or email mycancerstudyconnect@emergingmed.com. please visit www.bmsstudyconnect.com for more information on clinical trial participation. inclusion criteria: * documented progression from most recent line of therapy * measurable disease * 1 to 3 prior lines of therapy * subjects may be proteasome inhibitor naive or have received prior proteasome inhibitor therapy provided all the following criteria are met: 1. the subject did not discontinue any proteasome inhibitor due to intolerance or grade ≥ 3 toxicity 2. the subject is not refractory to any proteasome inhibitor, defined as progression during treatment or within 60 days after the last dose 3. the subject previously achieved a partial response (pr) or better to previous proteasome inhibitor (pi) exclusion criteria: * monoclonal gammopathy of undetermined significance (mgus), smoldering myeloma, or waldenstrom's macroglobulinemia * active plasma cell leukemia * known human immunodeficiency virus (hiv) infection or active hepatitis a, b, or c

Keywords: relapsed/refractory multiple myeloma
medico-economic analysis of management of flail chest between medical treatment and surgical treatment with stracos

Conditions: Polytraumatises With Rib Fractures

Summary: optimize the management of polytraumatises with flail chest: surgical treatment stracos by decreasing the length of stay and the late complications: pain chronicles, quality of life, respiratory function


Eligibility criteria:
inclusion criteria: * patients with flail chest including bifocal fracture of three or more consecutive ribs in at least two places with or without paradoxical movement * the surgical procedure was performed in the first 48 hours after admission * pathology with prognosis for survival 6-month-old inferior exclusion criteria: * paraplegia or tetraplegia * patients having the necessity of neurosurgical treatment or reanimation of neurosurgical * aorta hematoma or rupture * ß-hcg positive in women * titanium allergy
exercise and glycemic control in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Hyperglycemia

Summary: hyperglycemia is an independent risk factor for the development of diabetic complications in type 2 diabetes. exercise improves glycemic control, however, the role of exercise characteristics (e.g. intensity, type of exercise, timing, frequency) remains to be elucidated. this study aims to assess the effect of several exercise characteristics on hyperglycemia in various subgroups of type 2 diabetes patiënts.


Eligibility criteria:
impaired glucose tolerant subjects inclusion criteria: * bmi 25 - 35 kg/m2 * impaired glucose tolerant (according to ada guidelines) exclusion criteria: * cardiac disease (cardiac event in the last 5 years) * type 2 diabetes * use of orale blood glucose lowering medication or exogenous insulin * hba1c \>10% insulin treated type 2 diabetes patients inclusion criteria: * bmi 25 - 35 kg/m2 * insulin therapy * diagnosed with type 2 diabetes \>2 yr exclusion criteria: * cardiac disease (cardiac event in the last 5 years) * hba1c \>10% type 2 diabetes patients on oral blood glucose lowering medication inclusion criteria: * bmi 25 - 35 kg/m2 * diagnosed with type 2 diabetes \>2 yr exclusion criteria: * cardiac disease (cardiac event in the last 5 years) * hba1c \>10% * use of exogenous insulin

Keywords: continuous glucose monitoring system exercise
cheese and human health

Conditions: Cardiovascular Disease

Summary: the aim of this study is to examine if a diet rich in cheese will have a beneficial effect on risk markers of cardiovascular disease compared to a diet rich in butter. the primary parameters are total cholesterol as well as ldl-, hdl cholesterol and triacylglycerol (tag). the secondary parameters are hscrp, markers of insulin resistance, fasting insulin and glucose (homa). furthermore bloodpressure is measured.


Eligibility criteria:
inclusion criteria: * sign written consent * age: 20-70 * bmi: 20-32 * refrain from dietary supplements and blood donations prior to, and during the study exclusion criteria: * known or suspected abuse of alcohol, drugs or medication * poor compliance * current or previously cardiovascular disease * diabetes mellitus or other severe chronic disease, including severe allergies
impact of early oral stimulation on reducing cardiorespiratory events and transition to oral feeding in preterm infants

Conditions: Preterm Infants

Summary: to assess whether an oral stimulation program, before the introduction of oral feeding, enhances the cardiorespiratory manifestations (episodes of oxygen désaturations, and/or apnea- bradycardia), and the oral feeding performance, in preterm infants born between 26 to 29 weeks of gestation age.

preterm infant were randomized into an experimental or an control group. infants in the experimental group receive an oral stimulation program consisting of stimulation of the oral structures during 10 consecutive days. infant in the control group receive no stimulation only non nutritive sucking during feeding. both were administered twice per day, during 20 minutes, 48 hours after discontinuation of nasal continuous positive air pressure. a long term evaluation of oral feeding difficulties and neuromotor development are organized.

Eligibility criteria:
inclusion criteria: * children whose born term is included between 26 and 29sa past and whose postnatal age is lower or more equal in 33sa past, at the time of the inclusion. * term of certain child (calculated according to the date of the last rules and\\or a premature obstetric echography). * children devoid of neurological pathology making him(it) clinically unstable (echography transfontanellar and\\or intellectual mri, electroencephalogram normal, either, intraventricular bleeding of rank 1 and 2 of papile \[40\], or, intellectual abnormalities in the mri of type(chap) 1 - 4 according to the classification of modified paneth \[41\]. (annex x) * children devoid of infectious pathology making him(it) clinically unstable (protein c-reactive lower than 7). * in case of ebb gastroenteritis - esophageal symptomatic ( rgo): the child will be treated(handled), by oral route, by location + thickening +/-prokinetic +/-inhibitor pumps in proton. * according to a protocol of service, all the premature babies of less than 32. exclusion criteria: * born child \> 29 limited companies. * child not included at the postnatal age of 33 past(over) limited companies. * child presenting a genic syndrome, an evolutionary neurological disease, a pathology malformative. * child presenting a bleeding intraventricular of rank 3-4 \[ 40 \], intellectual abnormalities in the mri of type(chap) 5 and 6 according to the classification of modified paneth \[ 41 \], an ulcer-necrotizing entérocolitis. * child among whom both relatives(parents) or legal representatives refused that their child participates in the study.

Keywords: preterm infants born between 26 to 29 weeks of gestation age.
the transplant cohort of the german center for infection research

Conditions: Infections; Transplant Complication; Transplant Failure; Immunosuppression

Summary: medical data and biological samples obtained from transplant patients are collected and managed across germany with the help of the dzif transplant cohort. the data and samples form the basis of scientific studies which investigate the connections between numerous factors influencing an organ's susceptibility to infection and organ function.

infections in transplant recipients have a decisive impact on graft function and survival of the transplant recipient, but many issues are still poorly understood. for example, little is known about the long-term consequences of many infections on graft survival/function and graft- versus-host disease (gvhd), the role of individual susceptibility to bacterial, viral and fungal colonisation under immune suppression, the evolution of the antiviral t cell repertoire, the long- term impact of antiviral therapy on graft and patient survival or changes in the physiological microbiome that may have a bearing on colonisation with pathogenic microbes. taking advantage of the fact that most of the university hospitals with sizeable transplantation programs in germany are also dzif partners, we will establish a large multicentre prospective observational cohort of transplant recipients.

Eligibility criteria:
inclusion criteria: * consent * undergone transplantation of kidney, pancreas, liver, heart or stem cells exclusion criteria: * no consent
cimex lectularius or bed bugs : vector of infectious agents and pathogenic role

Conditions: Sting

Summary: during the last years, the investigators were the witness to the increase of a old emerging pest due to bed bugs (cimex lectularius) in the world. insecticides resistances apparitions and internationals transports increases seem to be the reasons of the pest. cimex lectularius as vector of parasites, bacteria or virus was often suggested although not much observation are recently investigated in france. this study intends to examine the vectorial ability and the direct pathogenicity of cimex lectularius.


Eligibility criteria:
inclusion criteria: * on the site of takings presence of insects and eggs evoking bedbugs of beds. the identification of certainty will be made in the laboratory. all the insects not apartment to the family of cimicidae (criterion of exclusion) are thrown(cast) in trash cans of laboratories for organic products. * voluntary patients after reading of the information sheet and the signature of the consent * membership of the patient in the national insurance scheme exclusion criteria * on the site of takings absence of insects and eggs evoking bedbugs of beds * during the identification of certainty in the laboratory, the captured insects do not make parties of the family of cimicidae * the subjects deprived of freedom. * patients cancelling their consent. * patients violating the protocol of search(research)

Keywords: bed bugs cimex insects bites
central obesity and disease risk in japanese americans

Conditions: Cardiovascular Diseases; Heart Diseases; Atherosclerosis; Hypertension; Obesity; Diabetes Mellitus, Non-insulin Dependent; Hyperinsulinism; Insulin Resistance; Coronary Arteriosclerosis; Diabetes Mellitus; Metabolic Syndrome X

Summary: to conduct a longitudinal study of central obesity and related risk factors found to be associated with hypertension and atherosclerotic cardiovascular disease (ascvd) in a previously-examined cross-sectional cohort of second-generation japanese americans and in a newly-recruited cohort of third generation japanese americans.

background: the study was conducted in response to a program announcment issued in 1991 on obesity and tests the hypothesis that atherosclerotic cardiovascular disease (ascvd), hypertension, and/or non-insulin dependent diabetes mellitus (niddm) develop in japanese americans when there is a truncal pattern of weight gain (central adiposity), which is in turn accompanied by insulin resistance, hyperinsulinemia, and lipid abnormalities. this cluster of abnormalities has been called 'syndrome x'. it is postulated that 'syndrome x' develops in japanese americans in response to environmental (behavioral) factors, many of which reflect 'westernization' in this ethnic group. the research plan focuses upon the relationship between central obesity and metabolic changes and disease outcomes associated with 'syndrome x' along with the behavioral variables that potential risk factors for the development of this cluster of abnormalities. design narrative: the cohort was re-examined for diabetes, hypertension, coronary heart, disease, peripheral vascular disease, and a number of potential coronary heart disease risk factors including medical history, health practice, social history, diet, glycosylated hemoglobin, insulin, proinsulin, c-peptide, glucose, anthrometric measurements, lipids, and computed tomography on the thorax, abdomen, and thigh.

Eligibility criteria:
no eligibility criteria
mood and cognitive outcome after heart transplantation (the moodheart study)

Conditions: Psychiatric Diagnosis; Cognition Disorders

Summary: the investigators aim at characterizing neuropsychiatric consequences of heart transplantation (htx) and at assessing the impact of depressive symptoms after htx on mortality and cardiac allograft vasculopathy (cav).


Eligibility criteria:
inclusion criteria: * participant in one of two former studies and heart transplanted at the time of inclusion into this former study exclusion criteria: * cognitively not capable to consent to participation and/or * insufficient fluent in the norwegian language to complete both psychiatric and neuropsychological assessment

Keywords: psychiatric morbidity cognitive function heart transplantation mortality cardiac allograft vasculopathy
effects of immunonutrition on the improvement of postoperative adjuvant chemotherapy related adverse reactions in patients with gastrointestinal tumors

Conditions: Gastrointestinal Tumors; Immunonutrition; Postoperative Adjuvant Chemotherapy

Summary: evaluate the effects of suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. the main endpoint of the study was the incidence of chemotherapy related adverse reactions (including bone marrow suppression, nausea and vomiting, diarrhea, and mucositis) in patients after two cycles of chemotherapy. the secondary endpoint indicators were: quality of life score (eortc-qlq-c30), nutritional risk score (pg-sga, nrs2002), nutritional assessment indicators, changes in immune microenvironment, analysis of psychological status, survival time (1-year progression free survival rate), treatment tolerance (dose intensity, rate of treatment interruption, delay), etc.


Eligibility criteria:
inclusion criteria: 1. subjects voluntarily and sign an informed consent form; 2. age ≥ 18 years old and ≤ 75 years old; 3. patients with stage ii-iii gastrointestinal malignancies with clear pathological diagnosis and undergoing radical surgery 4. no adjuvant chemotherapy received after surgery 5. the eastern cancer collaborative group's physical state score (ecog) is 0-2 points; 6. no contraindications to chemotherapy and the use of fluorouracil based chemotherapy regimens; exclusion criteria: 1. allergy to the components of immune nutrients, allergic constitution, or other inability to eat; 2. participated in other drug or food clinical trials within 2 months prior to enrollment; 3. having a history of immune deficiency, including hiv testing positive, or having other acquired or congenital immune deficiency diseases, or having a history of organ transplantation, or active infections that are not suitable for chemotherapy (as determined by the researcher); 4. subjects cannot guarantee compliance after participating in the study; 5. other researchers believe that it is not suitable for enrollment.